Denosumab improves glucose parameters in patients with impaired glucose tolerance: a systematic review and meta-analysis

OBJECTIVE: Receptor activator of NF-κβ ligand (RANKL) is crucial for the development of hepatic insulin resistance and poor glucose uptake; therefore, inhibiting RANKL with Denosumab could improve fasting plasma glucose (FPG) and insulin (FPI). METHODS: A systematic review was conducted to evaluate...

Descripción completa

Detalles Bibliográficos
Autores principales: Pacheco-Soto, Blanca T., Elguezabal-Rodelo, Rebeca Garazi, Porchia, Leonardo M., Torres-Rasgado, Enrique, Pérez-Fuentes, Ricardo, Gonzalez-Mejia, M. Elba
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Diabetes
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8525927/
https://www.ncbi.nlm.nih.gov/pubmed/34676131
http://dx.doi.org/10.1080/21556660.2021.1989194

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8525927/
https://www.ncbi.nlm.nih.gov/pubmed/34676131
http://dx.doi.org/10.1080/21556660.2021.1989194

Ejemplares similares